These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 19578775)

  • 1. Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.
    Stathopoulos GP; Koutantos J; Vaslamatzis MM; Athanasiadis A; Papadopoulos G; Labrodimou G; Stathopoulos J; Rigatos S
    Oncol Rep; 2009 Aug; 22(2):345-8. PubMed ID: 19578775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination.
    Athanasiadis A; Tsavdaridis D; Rigatos SK; Athanasiadis I; Pergantas N; Stathopoulos GP
    Anticancer Res; 2003; 23(3C):3085-8. PubMed ID: 12926166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ; Hernandez-McClain J; Henary H
    Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
    Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M
    Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.
    Raghavan D; Brandes LJ; Klapp K; Snyder T; Styles E; Tsao-Wei D; Lieskovsky G; Quinn DI; Ramsey EW
    J Urol; 2005 Nov; 174(5):1808-13; discussion 1813. PubMed ID: 16217292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
    Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
    J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.
    Amin A; Halabi S; Gelmann EP; Stadler W; Vogelzang N; Small E
    Urol Oncol; 2004; 22(5):398-403. PubMed ID: 15464920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].
    El Demery M; Pouessel D; Avancès C; Iborra F; Rebillard X; Faix A; Ségui B; Delbos O; Ayuso D; Culine S
    Prog Urol; 2006 Jun; 16(3):320-3. PubMed ID: 16821344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.
    Amato RJ; Teh BS; Henary H; Khan M; Saxena S
    Urol Oncol; 2009; 27(2):165-9. PubMed ID: 18367115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?
    Odrazka K; Vaculikova M; Dolezel M; Petera J; Moravek P; Prosvic P; Zoul Z; Vosmik M; Dolezal J; Simakova E
    Oncol Rep; 2005 Oct; 14(4):1077-81. PubMed ID: 16142375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.
    Schmidt U; Bilkenroth U; Linné C; Fuessel S; Kraemer K; Froehner M; Wirth MP; Meye A
    Int J Oncol; 2004 Jun; 24(6):1393-9. PubMed ID: 15138579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy.
    Romero S; Stanton G; DeFelice J; Schreiber F; Rago R; Fishman M
    Urol Oncol; 2007; 25(4):284-90. PubMed ID: 17628293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
    Banu E; Banu A; Medioni J; Levy E; Thiounn N; Mejean A; Andrieu JM; Oudard S
    Prostate; 2007 Oct; 67(14):1543-9. PubMed ID: 17705243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.
    Heng DY; Chi KN
    Can J Urol; 2006 Dec; 13(6):3335-9. PubMed ID: 17187697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
    Samelis GF; Kalofonos H; Adamou A; Kosmides P; Skarlos D; Aravantinos G; Kiamouris C; Adimchi O; Fountzilas G; Dimopoulos AM
    Urology; 2005 Aug; 66(2):382-5. PubMed ID: 16098366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
    Numata K; Miura N; Azuma K; Karashima T; Kasahara K; Nakatsuzi H; Hashine K; Sumiyoshi Y
    Hinyokika Kiyo; 2007 Feb; 53(2):99-104. PubMed ID: 17352158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.